Is there any significant news for Akra?
No significant news for AKRA in the past two years. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock quotes are delayed as per exchange requirements.
How much of Akero Therapeutics'stock is owned by insiders?
In the past three months, Akero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $937,710.00 in company stock. Only 7.09% of the stock of Akero Therapeutics is held by insiders. 81.27% of the stock of Akero Therapeutics is held by institutions.
Will Akra be confirmed in Wave 3?
AKRA is testing the price level of 3960. if it breaks, then AKRA is confirmed in wave3 and the price will rally until the maximum price target is at 4750. Currently buyable at PB or price contraction, the stock showed a very interesting cup with handle pattern.
Where can I buy Akro shares?
Shares of AKRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
JIIPE to Host World's Largest Smelter Complex with Custom Port and Jetty Facilities
Indonesia 4.0: JIIPE Designated Special Economic Zone by President Widodo
Indonesia's newest Special Economic Zone (SEZ), Java Integrated Industrial and Port Estate (JIIPE), announced it is poised to reach its target of $17 billion in investment and create 20,000 new jobs, as it confirms new major investor Freeport Indonesia (PTFI).
Key Stock Data
Java Integrated Industrial Ports and Estate (JIIPE) owned by PT AKR Corporindo Tbk (IDX: AKRA.JK) and Pelindo III is officially ratified as a Technology & Manufacturing Special Economic Zone (SEZ) per Government Regulation (PP) No. 71 of 2021 dated June 28, signed by the President of the Republic of Indonesia, Joko Widodo.
Short Interest ()
The total number of shares of a security that have been sold short and not yet repurchased.
Per-Share Earnings, Actuals and Estimates
Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades.
What is the ticker symbol for Akero Therapeutics?
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock quotes are delayed as per exchange requirements. Fundamental company data and analyst estimates provided by FactSet.
What is Akero Therapeutics?
Akero Therapeutics trades on the NASDAQ under the ticker symbol "AKRO."
What is marketbeat ratings?
Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.
Where is Akero Therapeutics located?
MarketBeat's community ratings are surveys of what our community members think about Akero Therapeutics and other stocks. Vote “Outperform” if you believe AKRO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AKRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Is Akero Therapeutics a buy?
Akero Therapeutics' mailing address is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 487-6488 or via email at [email protected].
Does Akero Therapeutics pay dividends?
Akero Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
